Theravance Biopharma
901 Gateway Boulevard
South San Francisco
California
94080
United States
Tel: 650-808-6000
Website: http://www.theravance.com/
About Theravance Biopharma
Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.
In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (the Closed Triple), currently in development for the treatment of COPD and asthma.
248 articles about Theravance Biopharma
-
Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares - June 25, 2021
6/25/2021
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced the pricing of its underwritten public offering of 6,700,000 ordinary shares at a price to the public of $15.00 per share.
-
Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19
6/21/2021
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, announced top-line results from its Phase 2 study of 3 mg once-daily nezulcitinib compared to placebo, each in combination with standard of care.
-
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry.
-
Theravance Biopharma to Participate in an Upcoming Investor Conference - May 06, 2021
5/6/2021
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in an investor event
-
Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
5/4/2021
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter of 2021
-
Theravance Biopharma to Report First Quarter 2021 Financial Results on May 4, 2021
4/20/2021
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its first quarter 2021 financial results and provide a business update after market close on Tuesday, May 4, 2021.
-
Theravance Biopharma to Participate in an Upcoming Investor Conference - Mar 02, 2021
3/2/2021
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in a pre-recorded Fireside Chat at the H.C.
-
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
2/23/2021
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2020.
-
Theravance Biopharma to Participate in Upcoming Investor Conferences - Feb 10, 2021
2/10/2021
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in investor events
-
Theravance Biopharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021
2/9/2021
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its fourth quarter and full year 2020 financial results and provide a business update after market close on Tuesday, February 23, 2021.
-
Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference
1/5/2021
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, will webcast its presentation at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 2:00 p.m. ET.
-
Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference
11/17/2020
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines
-
Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update
11/5/2020
YUPELRI® (revefenacin) share of the nebulized COPD market increased to 17.4% through July 2020 (up from 16% in April 2020) and achieved brand profitability on a stand-alone basis
-
Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020
10/22/2020
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its third quarter 2020 financial results and provide a business update after market close on Thursday, November 5, 2020.
-
Theravance Biopharma to Present at Upcoming Investor Conferences - Sep 01, 2020
9/1/2020
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast Management presentations as follows:
-
Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
8/6/2020
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter ending June 30, 2020. Revenue for the second quarter 2020 was $15.0 million
-
Theravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020
7/27/2020
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2020 financial results and provide a business update after market close on Thursday, August 6, 2020.
-
BioSpace Movers & Shakers, July 10
7/10/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors
7/2/2020
Theravance Biopharma, Inc. announced the appointment of Deepika R.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.